ARTICLE | Company News
Sorrento gene/cell therapy, cancer news
June 8, 2015 7:00 AM UTC
Sorrento established TNK Therapeutics Inc., a wholly owned subsidiary to develop chimeric antigen receptor tumor-attacking Neukoplasts (CAR-TNKs) and other cellular and immunotherapies for solid tumor...